Differential diagnosis and treatment options in paranasal sinus cancers

Larry L. Myers, Lance E. Oxford

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Paranasal sinus malignancies are challenging to treat. Most patients present with advanced lesions, often with intracranial or intraorbital extension, and have a poor overall prognosis. Given the low incidence and diverse pathologies of paranasal sinus cancers, it is extremely difficult to perform prospective, randomized clinical trials to compare different treatment approaches. Improving the prognosis of these cancers continues to be a difficult task, even in light of advances in surgical techniques, radiation delivery techniques, and new chemotherapeutic agents. Craniofacial resection techniques developed in the past few decades have cured many patients with skull base invasion, who would have been considered unresectable in the past. Furthermore, improvements in radiation therapy can allow more accurate administration to the desired region, with decreased damage to surrounding structures such as the orbit and brain. Aggressive and oncologically sound surgical resection combined with radiation therapy remains the treatment of choice for most patients. Finally, advances in the diagnosis and staging by use of molecular or DNA markers of tumor behavior may allow for more directed therapy.

Original languageEnglish (US)
Pages (from-to)167-186
Number of pages20
JournalSurgical Oncology Clinics of North America
Volume13
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Paranasal Sinus Neoplasms
Differential Diagnosis
Radiotherapy
Neoplasms
Paranasal Sinuses
Skull Base
Orbit
Genetic Markers
Therapeutics
Randomized Controlled Trials
Radiation
Pathology
Incidence
Brain

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Differential diagnosis and treatment options in paranasal sinus cancers. / Myers, Larry L.; Oxford, Lance E.

In: Surgical Oncology Clinics of North America, Vol. 13, No. 1, 01.2004, p. 167-186.

Research output: Contribution to journalArticle

@article{052ddefb56fd408eafaaf814f1c6bb66,
title = "Differential diagnosis and treatment options in paranasal sinus cancers",
abstract = "Paranasal sinus malignancies are challenging to treat. Most patients present with advanced lesions, often with intracranial or intraorbital extension, and have a poor overall prognosis. Given the low incidence and diverse pathologies of paranasal sinus cancers, it is extremely difficult to perform prospective, randomized clinical trials to compare different treatment approaches. Improving the prognosis of these cancers continues to be a difficult task, even in light of advances in surgical techniques, radiation delivery techniques, and new chemotherapeutic agents. Craniofacial resection techniques developed in the past few decades have cured many patients with skull base invasion, who would have been considered unresectable in the past. Furthermore, improvements in radiation therapy can allow more accurate administration to the desired region, with decreased damage to surrounding structures such as the orbit and brain. Aggressive and oncologically sound surgical resection combined with radiation therapy remains the treatment of choice for most patients. Finally, advances in the diagnosis and staging by use of molecular or DNA markers of tumor behavior may allow for more directed therapy.",
author = "Myers, {Larry L.} and Oxford, {Lance E.}",
year = "2004",
month = "1",
doi = "10.1016/S1055-3207(03)00115-7",
language = "English (US)",
volume = "13",
pages = "167--186",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Differential diagnosis and treatment options in paranasal sinus cancers

AU - Myers, Larry L.

AU - Oxford, Lance E.

PY - 2004/1

Y1 - 2004/1

N2 - Paranasal sinus malignancies are challenging to treat. Most patients present with advanced lesions, often with intracranial or intraorbital extension, and have a poor overall prognosis. Given the low incidence and diverse pathologies of paranasal sinus cancers, it is extremely difficult to perform prospective, randomized clinical trials to compare different treatment approaches. Improving the prognosis of these cancers continues to be a difficult task, even in light of advances in surgical techniques, radiation delivery techniques, and new chemotherapeutic agents. Craniofacial resection techniques developed in the past few decades have cured many patients with skull base invasion, who would have been considered unresectable in the past. Furthermore, improvements in radiation therapy can allow more accurate administration to the desired region, with decreased damage to surrounding structures such as the orbit and brain. Aggressive and oncologically sound surgical resection combined with radiation therapy remains the treatment of choice for most patients. Finally, advances in the diagnosis and staging by use of molecular or DNA markers of tumor behavior may allow for more directed therapy.

AB - Paranasal sinus malignancies are challenging to treat. Most patients present with advanced lesions, often with intracranial or intraorbital extension, and have a poor overall prognosis. Given the low incidence and diverse pathologies of paranasal sinus cancers, it is extremely difficult to perform prospective, randomized clinical trials to compare different treatment approaches. Improving the prognosis of these cancers continues to be a difficult task, even in light of advances in surgical techniques, radiation delivery techniques, and new chemotherapeutic agents. Craniofacial resection techniques developed in the past few decades have cured many patients with skull base invasion, who would have been considered unresectable in the past. Furthermore, improvements in radiation therapy can allow more accurate administration to the desired region, with decreased damage to surrounding structures such as the orbit and brain. Aggressive and oncologically sound surgical resection combined with radiation therapy remains the treatment of choice for most patients. Finally, advances in the diagnosis and staging by use of molecular or DNA markers of tumor behavior may allow for more directed therapy.

UR - http://www.scopus.com/inward/record.url?scp=1542357319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542357319&partnerID=8YFLogxK

U2 - 10.1016/S1055-3207(03)00115-7

DO - 10.1016/S1055-3207(03)00115-7

M3 - Article

C2 - 15062368

AN - SCOPUS:1542357319

VL - 13

SP - 167

EP - 186

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 1

ER -